Genetic markers to predict polygenic disease: A new problem for social genetics

QJM: An International Journal of Medicine

Volumn 92, Issue 4, 1999, Pages 223-232

  Galton, D J ^a   Ferns, G A A ^a,b  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E4; BLOOD CLOTTING FACTOR 5 LEIDEN; LIPOPROTEIN LIPASE;

ALZHEIMER DISEASE; CYSTIC FIBROSIS; DUCHENNE MUSCULAR DYSTROPHY; EMPLOYMENT; GENE MUTATION; GENETIC DISORDER; GENETIC MARKER; HUMAN; HYPERTRIGLYCERIDEMIA; INSURANCE; LAW; MULTIFACTORIAL INHERITANCE; NOTE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; THROMBOEMBOLISM; VEIN THROMBOSIS;

EID: 0032964532     PISSN: 00335622     EISSN: None     Source Type: Journal    
DOI: 10.1093/qjmed/92.4.223     Document Type: Note

References (52)

1. Dammerman M, Breslow JI. Genetic basis of lipoprotein disorders. Circulation 1995; 91:505-12.
2. Breslow JI. Apolipoprotein genes and atherosclerosis. J Clin Invest 1992; 70:377-84.
3. Rees A, Shoulders CC, Stocks J, Galton DJ, Baralle FE. DNA polymorphism adjacent to human apoprotein A-1 gene: relation to hypertriglyceridaemia. Lancet 1983; 1:444-6.
4. Rees A, Stocks J, Williams LG, et al. DNA polymorphisms in the apolipoprotein C-III and insulin genes and atherosclerosis. Atherosclerosis 1985; 58:269-75.
5. Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1988; 240:622-30.
6. Ravelingien N, Pector JC, Velu T. Contribution of molecular oncology in the detection of colorectal carcinomas. Acta Gastroenterol Belg 1995; 58:270-3.
7. Cho Y, Gorina S, Jeffrey PD, Pavletich NP. Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations. Science 1994; 265:346-55.
8. Montague CT, Farooqi IS, Whitehead JP, et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 1997; 387:903-8.
9. Hobbs HH, Brown MS, Goldstein JL. Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. Hum Mutat 1992; 1:445-66.
10. Mahley RW, Innerarity TL, Rall SC, Jr, Weisgraber KH. Lipoproteins of special significance in atherosclerosis. Insights provided by studies of type III hyperlipoproteinemia. Ann N Y Acad Sci 1985; 454:209-21.
11. Schneider WJ, Kovanen PT, Brown MS, et al. Familial dysbetalipoproteinemia. Abnormal binding of mutant apoprotein E to low density lipoprotein receptors of human fibroblasts and membranes from liver and adrenal of rats, rabbits, and cows. J Clin Invest 1981 Oct; 68:1075-85.
12. Hitman GA, Tarn AC, Winter RM, et al. Type 1 (insulin-dependent) diabetes and a highly variable locus close to the insulin gene on chromosome 11. Diabetologia 1985; 28:216-22.
13. Raffel LJ, Hitman GA, Toyoda H, Karam JH, Bell GI, Rotter JI. The aggregation of the 5′ insulin gene polymorphism in insulin dependent (type I) diabetes mellitus families. J Med Genet 1992 Jul; 29:447-50.
14. Humphries SE, Talmud PJ. Apolipoprotein C111 gene variation and dyslipidaemia. Current Opin Lipidol 1997; 8:154-8.
15. Hayden MR, Kirk H, Clark C, et al. DNA polymorphisms in and around the Apo-A1-CIII genes and genetic hyperlipidemias. Am J Hum Genet 1987; 40:421-30.
16. Dammerman M, Sandkuijl LA, Halaas JI, Chung W, Breslow JI. An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3′ untranslated region polymorphisms. Proc Natl Acad Sci USA 1993; 90:4562-6.
17. Zeng Q, Dammerman M, Takada Y, Matsunaga A, Breslow JL, Sasaki J. An apolipoprotein CIII marker associated with hypertriglyceridemia in Caucasians also confers increased risk in a west Japanese population. Hum Genet 1995; 95(4):371-5.
18. Hobbs HH, Russell DW, Brown MS, Goldstein JL. The LDL receptor locus in familial hypercholesterolemia: mutational analysis of a membrane protein. Ann Rev Genet 1990; 24:133-70.
19. Russell DW, Lehrman MA, Sudhof TC, et al. The LDL receptor in familial hypercholesterolemia: use of human mutations to dissect a membrane protein. Cold Spring Harb Symp Quant Biol 1986; 51(Pt 2):811-9.
20. Havel RJ. Analysis of angiographic trial data in women. Drugs 1994; 47(Suppl 2):11-15.
21. Betteridge DJ, Durrington PN, Fairhurst GJ, et al. Comparison of lipid-lowering effects of low-dose fluvastatin and conventional-dose gemfibrozil in patients with primary hypercholesterolemia. Am J Med 1994; 96:45S-54S.
22. Brandt B, Vogt U, Schlotter CM, et al. Prognostic relevance of aberrations in the erbB oncogenes from breast, ovarian, oral and lung cancers: double-differential polymerase chain reaction (ddPCR) for clinical diagnosis. Gene 1995; 159(1):35-42.
23. Ormiston W. Hereditary breast cancer. Eur J Cancer Care (Engl) 1996; 5:13-20.
24. WDelhanty JDA, Handyside AH, Winston RML. Preimplantation diagnosis. Lancet 1994; 343:1569-70.
25. Schulman JD, Edwards RG. Preimplantation diagnosis in disease control, not eugenics. Hum Reprod 1996; 11:463-4.
26. Stocks J, Holdsworth G, Galton D. Hypertriglyceridaemia associated with an abnormal triglyceride-rich lipoprotein carrying excess apolipoprotein C-III-2. Lancet 1979; 2:667-71.
27. Stocks J, Thorn JA, Galton DJ. Lipoprotein lipase genotypes for a common premature termination codon mutation detected by PCR-mediated site-directed mutagenesis and restriction digestion. J Lipid Res 1992; 33:853-7.
28. Mattu RK, Needham EW, Morgan R, et al. DNA variants at the LPL gene locus associate with angiographically defined severity of atherosclerosis and serum lipoprotein levels in a Welsh population. Arterioscler Thromb 1994; 14:1090-7.
29. Zhang Q, Cavanna J, Winkelman BR, et al. Common genetic variants of lipoprotein lipase that relate to lipid transport in patients with premature coronary artery disease. Clin Genet 1995; 48:293-8.
30. Duster T. Backdoor to Eugenics. Keegan Paul, USA, 1991.
31. Galton DJ, Galton CJ. Francis Galton: and eugenics today. J Med Ethics 1998; 24:99-105.
32. Hu S, Pattatucci AM, Patterson C, et al. Linkage between sexual orientation and chromosome Xq28 in males but not females. Nature Gen 1995; 11:248-56.
33. Peters T. Playing God: genetic determinism and human freedom. New York, Routledge, 1997.
34. Josefson D. FDA approves genetic test for women with breast cancer. Br Med J 1998; 316:168.
35. Brunner HG, Nelen MR, van Zandroort P, et al. X-linked borderline mental retardation with prominent behavioural disturbance: phenotype, genetic localisation and evidence for disturbed monoamine metabolism. Am J Hum Genet 1993; 52:1032-9.
36. Kitcher PK. The lives to come. London, Penguin Books, 1996.
37. Todd JA. Genetic analysis of type 1 diabetes using whole genome approaches. Proc Nat Acad Sci USA 1995; 92:8560-5.
38. Giardiello FM, Brensinger JD, Peterson GM, et al. The use and interpretation of commercial APC gene testing for familial adenomatous polyposis. N Engl J Med 1997; 336:823-7.
39. Genetic Tests. Association of British Insurers document L.627. Dec 1997.
40. Pokorski RJ. Insurance underwriting in the genetic era. Am J Hum Genet 1997; 60:205-16.
41. Convention on human rights and biomedicine. Council of Europe. European Treaty Series 164, Oviedo 1997.
42. Kevles DJ. In the name of eugenics. Harvard, Harvard University Press, 199?
43. Mailly F, Fisher RM, Nicaud V, et al. Association between the LPL-D9N mutation in the lipoprotein lipase gene and plasma lipid traits in myocardial infarction survivors from the ECTIM study. Atherosclerosis 1996; 122:21-8.
44. Fisher RM, Humphries SE, Talmud PJ. Common variation in the lipoprotein lipase gene: effects on plasma lipids and risk of atherosclerosis. Atherosclerosis 1997; 135:145-59.
45. Boerwinkle E, Sing CF. The use of measured genotype information in the analysis of quantitative phenotypes in man. 111. Simultaneous estimation of the frequencies and effects of the apolipoprotein E polymorphism and residual polygenetic effects on cholesterol and triglyceride levels. Ann Hum Genet 1987; 51:211-26.
46. Aird JM, Bentall HH, Roberts JAF. A relationship between cancer of the stomach and the ABO blood groups. Br Med J 1953; 1:799-801.
47. McDevitt HO, Bodmer WF. HLA immune response genes and disease. Lancet 1974; 1:1269-75.
48. Gylling H, Kontula K, Koivisto UM, Miettinen HE, Miettinen TA. Influence of apoprotein E and B gene polymorphisms on LDL levels during increased cholesterol intake. Arterioscl Thromb Vasc Biol 1997; 17:38-44.
49. Ferns GAA, Shelley CS, Stocks J, Rees A, Baralle F, Galton DJ. A DNA polymorphism of the apoprotein AII gene in hypertriglyceridaemia. Hum Genet 1986; 74:302-6.
50. Ferns GAA, Stocks J, Ritchie C, Galton DJ. DNA polymorphisms of the genes for apoprotein CIII and insulin in survivors of myocardial infarction. Lancet 1985; ii:300-1.
51. Ferns GAA, Galton DJ. Haplotypes of the human apoprotein A1/C111/AIV gene cluster in coronary atherosclerosis. Hum Genet 1986; 73:245-9.
52. Glasse A. US and Norway 'used insane Nazi-style tests'. The Times, 29.4.98.